We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

103 hedge funds and large institutions have $438M invested in CytomX Therapeutics in 2025 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 29 increasing their positions, 25 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

570% more call options, than puts

Call options by funds: $6.83M | Put options by funds: $1.02M

167% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 12

45% more capital invested

Capital invested by funds: $303M → $438M (+$136M)

24% more funds holding

Funds holding: 83 → 103 (+20)

16% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 25

82.02% less ownership

Funds ownership: 165.35% → 83.33% (-82%)

Holders
103
Holders Change
+20
Holders Change %
+24.1%
% of All Funds
1.35%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
32
Increased
29
Reduced
25
Closed
12
Calls
$6.83M
Puts
$1.02M
Net Calls
+$5.81M
Net Calls Change
+$4.08M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$13.9M
2
IC
Ikarian Capital
Texas
+$7.6M
3
PA
Perceptive Advisors
New York
+$6.05M
4
Citadel Advisors
Citadel Advisors
Florida
+$3.86M
5
VA
VR Adviser
New York
+$3.58M

Top Sellers

Rank Fund Capital Flow
1
Franklin Resources
Franklin Resources
California
-$13.1M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$9.04M
3
FFM
Fairmount Funds Management
Pennsylvania
-$8.85M
4
PM
Prosight Management
Texas
-$6.65M
5
VC
Vivo Capital
California
-$6.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of America
26
Bank of America
North Carolina
$3.21M +$2.25M +1,000,457 +20,970%
EAM
27
Exome Asset Management
New York
$2.38M +$1.68M +745,305 New
Assenagon Asset Management
28
Assenagon Asset Management
Luxembourg
$2.33M +$22.4K +9,947 +1%
Two Sigma Investments
29
Two Sigma Investments
New York
$2.33M +$1.29M +572,017 +363%
Acadian Asset Management
30
Acadian Asset Management
Massachusetts
$2.08M -$2.03M -903,311 -58%
State Street
31
State Street
Massachusetts
$2.06M +$13.4K +5,942 +0.9%
PM
32
Prosight Management
Texas
$1.8M -$6.65M -2,952,313 -84%
GCP
33
GSA Capital Partners
United Kingdom
$1.71M -$214K -94,835 -15%
II
34
Inspire Investing
Idaho
$1.67M +$1.18M +522,482 New
Dimensional Fund Advisors
35
Dimensional Fund Advisors
Texas
$1.44M +$604K +267,962 +146%
Goldman Sachs
36
Goldman Sachs
New York
$1.43M +$975K +433,075 +2,951%
First Trust Advisors
37
First Trust Advisors
Illinois
$1.28M +$905K +401,891 New
Jane Street
38
Jane Street
New York
$1.28M +$877K +389,399 +3,254%
Northern Trust
39
Northern Trust
Illinois
$1.24M -$136K -60,422 -13%
Morgan Stanley
40
Morgan Stanley
New York
$1.02M -$44.9K -19,918 -6%
Raymond James Financial
41
Raymond James Financial
Florida
$936K +$22.5K +10,000 +4%
Susquehanna International Group
42
Susquehanna International Group
Pennsylvania
$853K -$55K -24,411 -8%
HS
43
HighVista Strategies
Massachusetts
$820K +$579K +257,148 New
Bank of New York Mellon
44
Bank of New York Mellon
New York
$806K – – –
PWS
45
Precision Wealth Strategies
Missouri
$756K +$534K +237,081 New
PCM
46
Prelude Capital Management
New York
$659K +$465K +206,526 New
DP
47
Diadema Partners
New Jersey
$591K +$417K +185,286 New
Ameriprise
48
Ameriprise
Minnesota
$505K +$357K +158,329 New
Royal Bank of Canada
49
Royal Bank of Canada
Ontario, Canada
$486K -$205K -91,243 -37%
QC
50
Quadrature Capital
United Kingdom
$399K +$282K +125,035 New
1
2
3 4 5

CTMX Hedge Fund Activity: Q3 2025 in Review

103 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q3 2025, worth a combined $438M — up 45% from $303M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new CTMX positions and 12 closed out — a net gain of 20 holders — while 29 added to existing stakes and 25 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $13.9M. The largest seller was Franklin Resources, exiting entirely with an estimated $13.1M sold.

  • 103 institutional investors held CytomX Therapeutics (CTMX) as of Q3 2025, up from 83 in Q2 2025.
  • Funds reported $438M of CytomX Therapeutics stock for Q3 2025, up 45% quarter-over-quarter.
  • 32 funds opened new CytomX Therapeutics positions in Q3 2025 and 12 closed out, a net change of +20 holders.
  • The largest CytomX Therapeutics buyer in Q3 2025 was Fidelity Investments, an estimated $13.9M added.
  • The largest CytomX Therapeutics seller in Q3 2025 was Franklin Resources, an estimated $13.1M sold.

Based on aggregated 13F filings for Q3 2025.